SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility following a major earnings beat and raised guidance, as investors grapple with a 'sell-the-news' reaction after a massive year-to-date rally. The community is sharply divided between bulls defending the companys strong AI-driven memory cycle fundamentals and share buyback program, and bears who view the stock as overextended and susceptible to a correction.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is experiencing intense market volatility and significant downward pressure, with investors and the community debating concerns over child safety policies, user growth deceleration, and the company's long-term path to profitability. While some participants are actively shorting the stock, others view the sharp pullback as a potential accumulation opportunity for a long-term play on the platform's massive, persistent engagement.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following a significant earnings report that surpassed analyst expectations on both revenue and earnings per share, driven by strong growth in ad monetization and platform engagement. The community is actively debating the sustainability of these gains, with bulls focusing on Reddit's potential for margin expansion and international scaling, while bears remain skeptical about user growth metrics and ongoing share dilution.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is facing intense volatility and negative sentiment following the announcement of an 80 million dollar common stock and pre-funded warrant offering. The community is actively debating the necessity of this dilution, with many investors expressing deep frustration over capital management, leadership performance, and the looming threat of a further reverse split.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to a recently confirmed $7.5 million milestone payment from Boehringer Ingelheim and an upcoming R&D presentation, which have sparked heavy retail interest and speculation about the company's clinical pipeline. The community is actively debating the stock's potential for a significant squeeze against concerns surrounding dilution, a possible reverse stock split, and the company's historical volatility.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending following a massive earnings beat and guidance raise, with the community focused on the rapid adoption of its Athena AI platform and the company's strong revenue growth momentum. Investors and traders are actively debating the stock's potential for a profitability re-rating, with many highlighting its consistency in exceeding expectations and the perceived disconnect between its fundamental execution and recent price action.

General Dynamics Corp. is a global aerospace and defense company, which engages in design, engineering, and manufacturing to deliver solutions. It operates through the following business segments: Aerospace, Marine Systems, Combat Systems, and Technologies. The Aerospace segment includes the production of business jets, technology aircraft, repair, support and completion services. The Marine Systems segment involves the design and building of nuclear-powered submarines, surface combatant, and auxiliary ship design and construction. The Combat Systems segment focuses on manufacturing and integrating land combat solutions, wheeled and tracked combat vehicles, weapons systems, and munitions. The Technologies segment consists of services, technologies, and products for electronic hardware with its software. The company was founded on February 21, 1952 and is headquartered in Reston, VA.

General Dynamics Corp.

General Dynamics (GD) is trending as investors digest a strong earnings beat characterized by double-digit revenue growth and a record-breaking contract backlog. The community is actively debating the company's long-term resilience as a defensive staple amid high-level discussions surrounding a potential $1.5 trillion national defense budget and the strategic impact of massive shipbuilding contract modifications.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and momentum as traders aggressively target its nano-float structure for a short squeeze, leading to intense community debate over its pivot to telecommunications and sustainability of the rally. While bulls are focused on the lack of share availability and potential for further gains, skeptics are actively warning of a potential crash, citing past reverse splits and concerns regarding company operations.

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

iSpecimen is seeing significant community attention driven by a combination of low-float mechanics, speculation regarding potential acquisition activity, and recent strategic partnerships. Traders are actively debating the sustainability of its price action and the impact of its capital structure, with many watching for increased volume as a catalyst for a potential short squeeze.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is seeing heightened investor attention as the company continues its strategic pivot from pure Bitcoin mining toward AI infrastructure and data center operations. The community remains deeply divided, with bulls highlighting the long-term value of its expanded power capacity and institutional partnerships, while bears express frustration over the stock's volatility and reliance on capital-intensive mining operations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rati...

Alto Neuroscience (NYSE:ANRO) Earns "Buy" Rating from Chardan Capital

Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday...

Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High - Still a Buy?

Alto Neuroscience (NYSE:ANRO) Sets New 52-Week High - Should You Buy...

Alto Neuroscience (NYSE:ANRO)  Shares Down 7.2%   - Here's Why

Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% - Time to Sell...

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b...

Alto Neuroscience (NYSE:ANRO) Trading 8.8% Higher   - Here's What Happened

Alto Neuroscience (NYSE:ANRO) Shares Up 8.8% - Here's Why...

Alto Neuroscience (NYSE:ANRO) Trading Down 6.3%  - Time to Sell?

Alto Neuroscience (NYSE:ANRO) Shares Down 6.3% - What's Next...

Q1 Earnings Estimate for ANRO Issued By HC Wainwright

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Alto Neuroscience in a research note issued on Thursday...

Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird

Robert W. Baird decreased their price target on shares of Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating on the stock in a research note on Thursday...

<ul class="summary-bullets"><li>H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience.</li><li>Baird cut Alto’s price target to $38 from $41 but said the company’s depression pipeline remains the key driver of its valuation.</li><li>Jones Research’s latest price target implies a potential 100% upside to the stock’s current price.</li></ul>Shares of Alto Neuroscience (ANRO) slid about 7% on Thursday after disappointing results from a schizophrenia treatment study prompted multiple brokerages to become more cautious on the stock.On Wednesday, Alto Neuroscience <a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-schizophrenia-study-fails/cZ7HygQRIFi">said</a> its experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 Proof-of-Concept study. ALTO-101 did not show meaningful improvements in brain activity or cognitive measures compared to placebo.As a result, the biotech firm will not continue developing the drug for this use and will shift focus to other programs, including ALTO-207 for treatment-resistant depression. The company is also exploring partnership opportunities for a modified version of ALTO-101 that showed better safety and drug behavior.<h2 class="st-heading-2">Analyst Sees Pullback As Attractive Entry Point</h2>Jones Research cut Alto Neuroscience’s price target to $44 from $49, but kept a ‘Buy’ rating, according to The Fly. This implies a potential 100% upside to the stock’s current price of around $22.Analyst Justin Walsh said that while the stock’s weakness is justified, the market is underestimating Alto’s broader pipeline and sees the pullback as an attractive entry point.H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience, as the program was not a key part of its valuation, according to The Fly. The brokerage also highlighted the company’s strong cash position of $275 million, which supports its pipeline. H.C. Wainwright maintained its ‘Buy’ rating and $50 price target.Baird cut the company’s price target to $38 from $41 and maintained an ‘Outperform’ rating. Analyst Brian Skorney called the ALTO-101 Phase 2 failure disappointing, though expectations were already modest given the challenges in schizophrenia treatment. The firm said Alto’s depression pipeline remains the key driver of its valuation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/ANRO">ANRO</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user had expected a bigger drop.<stembedurl>http://stocktwits.com/Stef_DL/message/649289943</stembedurl>Year-to-date, the stock has gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/snbr-stock-on-track-to-decline-for-12th-straight-session/cZ7x67bRI8o">SNBR Stock On Track To Decline For 12th Straight Session – Retail Sees Buying Opportunity If Stock Dips Below $1</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point

Alto Neuroscience’s experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 study, leading to price target cuts from multiple brokerages.

Equity

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Current Price	$25.66
Prev Close	$24.30
Open	$24.60
Dividend Yield	0.00%
50-Day Moving Average	$22.39
Beta	1.69
Avg. Volume	315,173.77
PE Ratio	-11.43

52-Week High	$28.44
52-Week Low	$2.12
Market Capitalization	$776.28M
EPS (Annual)	-$2.19
Price to Book	5.42
Revenue Per Employee	$0.00

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANRO News

ANROAlto Neuroscience Inc.